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BACKGROUND: Non-steroidal anti-inflammatory drugs (NSAIDs) and hormone therapy (HT) independently decrease the risk
of colorectal cancer. However, their role in altering survival after a colorectal cancer diagnosis is not well established.
METHODS: We examined the association between the use of these common medications before diagnosis and colorectal cancer
survival among women in western Washington State diagnosed with incident colorectal cancer from 1997 to 2002. Cases were
ascertained using the Surveillance, Epidemiology and End Results cancer registry; mortality follow-up was completed through linkages
to the National Death Index. Cox proportional hazards regression was used to estimate hazard ratios (HRs) and 95% confidence
intervals (CIs).
RESULTS: We observed no overall association between colorectal cancer survival and pre-diagnostic NSAID use. However, when
stratified by tumour sub-site, NSAID use was associated with a reduced risk of colorectal cancer mortality for women diagnosed with
proximal (HR¼0.55; 95% CI: 0.32–0.92), but not distal or rectal (HR¼1.32; 95% CI: 0.83–2.10) tumours. The usage of HT was not
associated with colorectal cancer survival overall or by tumour sub-site.
CONCLUSION: Usage of NSAIDs before diagnosis may be associated with improved colorectal cancer survival among women
diagnosed with proximal tumours. The usage of HT does not appear to have a function in altering colorectal cancer mortality.
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Non-steroidal anti-inflammatory drug (NSAID) use and hormone
therapy (HT) use have each been consistently shown to be
associated with a significantly reduced risk of developing colo-
rectal cancer (Giovannucci et al, 1994; Newcomb and Storer, 1995;
Rossouw et al, 2002; Gambacciani et al, 2003; Chlebowski et al,
2004; Chan et al, 2005; Bardia et al, 2007; Newcomb et al, 2007b;
Baron, 2009; Cole et al, 2009). However, few studies have
investigated the role of these common medications in subsequent
mortality after a diagnosis of colorectal cancer.
Only three observational studies in the literature to date have
addressed the relationship between NSAID use and colorectal
cancer survival (Fuchs and Heseltine et al, 2005; Chan et al, 2009;
Zell et al, 2009). A study of stage III colorectal cancer patients
(n¼846 men and women combined) enrolled in a randomized
chemotherapy trial observed that consistent aspirin use was
associated with 52% lower risk of either cancer recurrence or
mortality (Fuchs and Heseltine et al, 2005). A report from the
Nurses’ Health Study (NHS) and Health Professionals Follow-up
Study, (n¼840 women; 439 men) found that regular aspirin use
after a diagnosis of colorectal cancer was associated with a 29%
reduced risk of colorectal cancer-specific mortality (Chan et al,
2009). Finally, a recent investigation in the California Teachers
Study (CTS) cohort (n¼621 women) observed that regular
NSAID use before diagnosis among women was associated with
a 42% reduced rate of colorectal cancer mortality (Zell et al, 2009).
Three previous studies have observed inverse associations
between regular HT use and the risk of death from colorectal
cancer (Calle et al, 1995; Slattery et al, 1999; Mandelson et al,
2003), although the design of one study precluded it from
distinguishing between the effects of HT on reduced cancer
incidence from those of HT on survival after diagnosis (Calle et al,
1995). In contrast, results from the Women’s Health Initiative and
a recent large, population-based study of women with large bowel
cancer both observed no association between HT use and
colorectal cancer survival (Ritenbaugh et al, 2008; Newcomb
et al, 2009).
We investigated the association between both NSAID use and
HT use before cancer diagnosis and subsequent death among
female colorectal cases identified from the population-based
Surveillance, Epidemiology and End Results (SEER) registry in
13 counties of western Washington State.
MATERIALS AND METHODS
Study population
Details of case ascertainment have been published elsewhere
(Newcomb et al, 2007a,b). Briefly, eligible case subjects included
women, aged between 50 and 74 years, residing in 13 counties
in western Washington State, who were diagnosed between 1997
and 2002 with incident, invasive colorectal cancer. Women aged
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in the Puget Sound counties (3 of the 13) were also eligible for
inclusion. Cases were reported to the Cancer Surveillance System,
a population-based registry that is part of the National Cancer
Institute’s SEER program. Eligibility was limited to English-
speaking subjects with available telephone numbers. With
physician approval, the study subjects received an introductory
letter in the mail and were followed-up with a telephone call.
A total of 1614 eligible women were identified. Of these cases,
100 were deceased, 151 were lost to follow-up before interview and
181 refused to participate or did not complete the baseline
interview, resulting in a final sample size of 1173 cases. Cases were
interviewed and enrolled an average of 8.1 months (s.d.¼3.2) after
colorectal cancer diagnosis. Analyses were restricted to Caucasian
women (n¼1051) because of sparse data among women of other
races. The study was approved by the Institutional Review Board of
the Fred Hutchinson Cancer Research Center in accordance with
assurances filed with and approved by the US Department of
Health and Human Services.
Exposure and covariate assessment
A structured 60-min telephone interview was used to obtain
information from all cases on established and potential risk factors
for colorectal cancer. Interviewer-collected information included
data on history of NSAID and exogenous hormone use, menstrual
and reproductive history, smoking history, height and weight,
history of colorectal cancer screening, first-degree family history of
cancer and demographic factors, such as age and race. For all
women, only potential exposures that occurred before a reference
date, approximately 2 years before diagnosis, were considered
in the analysis. The interview collected information on type and
duration of NSAID use (aspirin or ibuprofen) and HT use
(oestrogen only or combined oestrogen and progestin).
For NSAIDs, regular use was defined as use at least twice per
week for 1 month or greater. Ever use was defined as regular use of
any NSAID type at any point in time before the reference date.
Never users reported no use or less than the defined regular use
threshold before the reference date. Duration of NSAID use was
calculated using the reported years of regular use of any type of
NSAID medication; information on the reported frequency of use,
measured in pills per day on average, was also collected. An
NSAID-dose variable used in Cox models was created using both
the available duration and frequency information and included
the following categories: p1 time per day for p2 years (dose 1);
41 time per day for p2 years (dose 2); p1 time per day for
42 years (dose 3); and 41 time per day for 42 years (dose 4).
For HT, ever use was defined as use of any preparation type for
at least 6 consecutive months at any time before the reference date.
Never users reported no use or less than the defined ever use
threshold before the reference date. Duration of HT use was
calculated using the reported years of use of any type of HT
preparation.
Outcome
Vital status on all enrolled cancer cases was determined through
linkages to the National Death Index to obtain date and cause of
death; cause of death was classified using ICD10 coding conven-
tions. The National Death Index identifies known deaths with a
high degree of sensitivity, validity and completeness (Fillenbaum
et al, 2009). The primary outcome of interest was death due
to colorectal cancer. Time to death was evaluated from SEER-
recorded date of colorectal cancer diagnosis and National Death
Index-recorded date of death. Patients alive at the time of their last
known vital assessment were censored at that date, with the most
recent vital status linkage occurring in December 2009. Patients
dying of causes other than colorectal cancer were censored at their
recorded date of death.
Sub-site and stage of the colorectal tumour at diagnosis were
defined using SEER records. Advanced disease was defined as
colorectal cancer with distant metastasis at diagnosis; non-
advanced disease included local and regional stage disease at
diagnosis. Sub-site of disease was categorized using ICD10 codes:
proximal disease (C18.0–C18.5); distal disease (C18.6–C18.7); and
rectal disease (C19.9–C20.9).
Statistical analysis
Kaplan–Meier survival curves were generated for both NSAID use
(ever vs never) and HT use (ever vs never). The proportional hazards
assumption was evaluated graphically as well as statistically through
inclusion of interaction terms between exposures and current time in
Cox regression models (Ahmed et al, 2007). For both exposures
investigated, the proportional hazards assumption was not statisti-
cally violated for colorectal cancer-specific mortality.
Cox proportional hazards regression models were used to
estimate hazard ratios (HRs) and 95% confidence intervals (CIs)
for the association between pre-diagnostic NSAID use, HT use and
colorectal cancer-specific mortality. To increase comparability to
previous studies that excluded metastatic disease (Chan et al,
2009), analyses were restricted to cases diagnosed with local or
regional disease (n¼933). Cox regression models included the
following list of covariates selected a priori: age at cancer
diagnosis, body mass index at reference date, smoking status,
family history of colorectal cancer, history of preventive screening
and stage of disease at diagnosis. Additionally, the regression
models investigating each medication were adjusted for pre-
diagnostic use of the other medication (i.e., NSAID use adjusted
for pre-diagnostic HT use). Preventive screening was defined as
sigmoidoscopy or colonoscopy (endoscopy) screening that was
received at least 2 years before the diagnosis of colorectal cancer.
Categories of body mass index were defined as the following
in units of kgm
 2: not overweight o25.0, overweight 25.0–29.9,
obese X30.0 (Clinical Guidelines on the Identification, Evaluation,
and Treatment of Overweight and Obesity in Adults, 1998).
The multivariable Cox regression models were evaluated across
strata of tumour sub-site (proximal vs distal/rectal). Statistical
interaction between NSAID use, HT use and tumour sub-site was
investigated by the inclusion of interaction terms between the
respective medication use (yes/no) and tumour sub-site (proximal/
distal, rectal) in regression models. All statistical analyses were
performed using SAS software, version 9.1 (SAS Institute Inc.,
Cary, NC, USA); all P-values reported are two sided.
RESULTS
After an average of 6.3 years of follow-up after cancer diagnosis
and study enrolment, a total of 371 deaths from all causes and 274
deaths from colorectal cancer were ascertained. Among women
with non-advanced colorectal disease, 266 deaths from all causes
and 149 deaths specifically due to colorectal cancer were identified.
Approximately 50% of the women in the study population
reported ever using NSAIDs before their cancer diagnosis. Among
women at least 50 years of age, the proportion of ever HT users
was slightly higher than 55% (Table 1). Ever users of NSAIDs,
compared with never users, were more likely to have a family
history of colorectal cancer, have a history of preventive screening,
and to be obese. Although ever users of HT were also more likely
than never users to have a history of preventive screening, they
were less likely to be obese and showed no substantive differences
in previous family history of colorectal cancer compared with
never users. Greater proportions of both ever users of NSAIDs and
ever users of HT were diagnosed with localised tumours.
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with pre-diagnostic NSAID use was 0.88 (95% CI: 0.62–1.24)
(Table 2). We observed evidence of heterogeneity in the
association of NSAID use before diagnosis with colorectal cancer
survival according to the sub-site of the diagnosed colo-
rectal tumour (P-value for interaction¼0.03). Pre-diagnostic
NSAID use was significantly associated with improved colorectal
cancer survival among cases diagnosed with proximal disease
(HR¼0.55; 95% CI: 0.32–0.92). In contrast, we observed no
apparent association with survival among women diagnosed with
left-sided disease (Table 2). This null association was observed
among subgroups of left-sided disease, including cases diagnosed
with distal tumours (HR¼1.40; 95% CI: 0.62–3.19) and cases
diagnosed with rectal tumours (HR¼1.25; 95% CI: 0.70–2.22).
Colorectal cancer survival curves, based on NSAID use (ever vs
never), for both proximal tumours and distal/rectal tumours, are
presented in Figure 1.
The statistically significant reduction in the risk of colorectal
cancer mortality among proximal cases associated with pre-
diagnostic NSAID use was observed to be dose dependent
(P-trend¼0.01). Although women who reported use on average
not more than once per day for 2 years or less (dose 1) were not
observed to experience a reduced risk of colorectal cancer
mortality (HR: 1.06; 95% CI: 0.50–2.26), women who used NSAIDs
more than once a day for greater than 2 years (dose 4) experienced
approximately one quarter the risk of dying of colorectal
cancer (HR: 0.26; 95% CI: 0.07–0.88) compared with never users
(data not shown).
Estimates for aspirin and ibuprofen use were not observed to be
of similar magnitude, with a much stronger association present
among regular ibuprofen users. However, the limited number of
cases regularly using ibuprofen precludes any definitive conclu-
sions, and these type-specific differences should be investigated
further in studies adequately power to examine associations within
subgroups of NSAID type. The patterns of regular use for aspirin
and ibuprofen also differed substantially. Ibuprofen users
appeared to be using at higher doses (pills per day) on a more
regular basis than aspirin users (data not shown); the pattern of
use and not type of NSAID may, therefore, potentially account for
observed differences.
Pre-diagnostic HT use was not associated with the risk of colo-
rectal cancer mortality among cases (HR: 0.95; 95% CI: 0.66–1.35).
The association between pre-diagnostic HT use and colorectal
cancer survival was consistently null among cases reporting use
of oestrogen-only preparations as well as cases reporting use of
oestrogen plus progestin preparations. Additionally, the association
between pre-diagnostic HT use and colorectal cancer survival was
null among cases diagnosed with both proximal tumours and those
diagnosed with distal or rectal tumours. Longer durations of HT use
were also not observed to alter the risk of colorectal cancer mortality
after diagnosis. Finally, we did not observe any significant hetero-
geneity in the association of HT with colorectal cancer survival
according to NSAID use status (P-value for interaction¼0.29).
DISCUSSION
We observed an inverse association between NSAID use and
death due to colorectal cancer among Caucasian women diagnosed
with proximal disease. Women who regularly used NSAIDs
before diagnosis experienced approximately half the risk of
colorectal cancer mortality compared to never users. These women
experienced an approximate halving of risk of colorectal cancer
mortality compared with never users. This association was
observed to be dose-dependent, with reductions in colorectal
cancer mortality of greater magnitude associated with increasing
amounts of NSAID use. We did not, however, observe any evidence
of an association between HT use before diagnosis and colorectal
cancer survival, regardless of hormone preparation type, duration
of use or tumour characteristics at diagnosis.
Previous studies provide evidence that NSAID use may be
important for colorectal cancer survival after diagnosis (Fuchs and
Heseltine et al, 2005; Chan et al, 2009; Zell et al, 2009). The report
from the California Teachers Study observed a dose-dependent
improvement in colorectal cancer survival associated with NSAID
use before diagnosis (Zell et al, 2009). The NHS and Health
Professionals Follow-up Study (Chan et al, 2009) reported that any
association with improved survival was limited to post-diagnostic
NSAID use. However, cases from the NHS and Health Profes-
sionals Follow-up Study cohorts did not experience any significant
survival benefit associated specifically with post-diagnostic use if
they also reported aspirin use before their colorectal cancer
diagnosis (HR: 0.89; 95% CI: 0.59–1.35). These findings suggest
that NSAID use both before and after diagnosis may have an
important role in altering colorectal cancer survival.
Table 1 Characteristics of study women (n¼1051) according to
pre-diagnostic NSAID and HT use
NSAID use
a Hormone therapy
b
Never
(n¼507)
Ever
(n¼534)
Never
(n¼401)
Ever
(n¼519)
n % n % n % n %
Age at diagnosis
o50 years 59 11.6 61 11.4 ————
50–59 years 145 28.6 123 23.0 107 26.7 160 30.8
60–69 years 176 34.7 210 39.3 148 36.9 237 45.7
470 years 127 25.0 140 26.2 146 36.4 122 23.5
BMI (kgm
 2)
o25.0 231 45.6 193 36.1 146 36.4 209 40.3
25.0–29.9 156 30.8 157 29.4 119 29.7 168 32.4
X30.0 118 23.4 183 34.3 135 33.8 141 27.2
Menopausal status
b
Pre-menopausal 25 5.6 17 3.6 30 7.5 13 2.5
Natural menopause 245 54.7 223 47.2 252 62.8 216 41.7
Induced/other menopause 178 39.7 232 49.2 119 29.7 289 55.8
Family history of colorectal cancer
No 430 84.8 431 80.7 331 82.5 432 83.2
Yes 77 15.2 103 19.3 70 17.5 87 16.8
Smoking status
No 227 44.8 247 46.3 180 44.9 244 47.0
Former 183 36.1 211 39.5 149 37.2 197 38.0
Current 97 19.1 76 14.2 72 18.0 78 15.0
Preventive screening
No 470 90.7 475 88.0 373 93.0 461 88.8
Yes 37 7.3 59 11.0 28 7.0 58 11.2
Tumour sub-site
Proximal 224 44.2 255 47.8 185 46.1 257 44.4
Distal 133 26.2 132 24.7 111 27.7 121 23.3
Rectal 150 29.6 147 27.5 105 26.2 141 27.2
Stage of disease at diagnosis
Localized 193 38.3 234 43.8 162 40.5 230 44.5
Regional 257 51.0 237 44.4 184 46.0 242 46.8
Distant 54 10.7 63 11.8 54 13.5 45 8.7
Abbreviations: BMI¼body mass index, HT¼hormone therapy, NSAID¼
non-steroidal anti-inflammatory drug.
aNot all women responded to the interview
questions regarding medication use, resulting in missing data on NSAID use and
HT use for n¼10 women.
bPercentages and counts restricted to women at least
50 years of age (n¼930).
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association between NSAID use and colorectal cancer mortality
according to tumour sub-site. The NHS and Health Professionals
Follow-up Study examined potential differences according to
whether the tumour was located in the colon vs the rectum and
observed no heterogeneity. Our study is the first to report results
according to proximal vs distal or rectal tumour location, making
comparison of our results to previous survival studies difficult.
However, previous literature has reported a site-specific effect for
NSAIDs on the risk of developing incident colorectal cancer
(Rosenberg et al, 1991; Smalley et al, 1999; Mahipal et al, 2006),
with a stronger inverse association being observed for proximal
disease.
Our findings for HT are consistent with results from the
Women’s Health Initiative, as well as data from a large population-
based study of large bowel cancer, both of which showed no overall
association between HT use and colorectal cancer survival
(Ritenbaugh et al, 2008; Newcomb et al, 2009). Previous studies
that observed a statistically significant reduction in colorectal
cancer mortality associated with HT often failed to account for
important covariates, such as colorectal cancer screening or
NSAID use in their analyses (Slattery et al, 1999; Mandelson
et al, 2003). We did in fact observe different prevalences of both
screening and NSAID use among HT users compared with never
users in our study, highlighting the importance of accounting for
these potential confounders in analyses to obtain an unbiased
estimate of the effect of HT use before diagnosis on colorectal
cancer survival.
There are several plausible mechanisms by which NSAID use
before diagnosis could affect colorectal cancer mortality among
women. Prostaglandin synthases COX-1 and COX-2 are directly
inhibited by NSAIDs, altering prostaglandin production and
cellular inflammatory responses (Sheng et al, 1997; Brown and
DuBois, 2005; Rodriguez-Moranta and Castells, 2005; Wang and
Dubois, 2010). This alteration of prostaglandin production results
in the promotion of apoptosis, inhibition of angiogenesis and
disruption of processes crucial to tumour growth (Sheng et al,
2001; Chan, 2006; Wang and Dubois, 2006; Cha and DuBois, 2007;
Greenhough et al, 2009). The anti-inflammatory effects of NSAID
medications may also impact upon colorectal cancer survival
directly as inflammation has been linked to both colorectal cancer
incidence and cancer progression (Coussens and Werb, 2002;
Erlinger et al, 2004; Kim et al, 2008; Mantovani et al, 2008), and
multiple markers of systemic inflammation have been linked
specifically to colorectal cancer prognosis (Ishizuka et al, 2007;
Shiu et al, 2008; Roxburgh et al, 2009).
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Figure 1 Colorectal cancer survival according to pre-diagnostic NSAID use among women.
Table 2 HRs and 95% CIs for the association between NSAID and HT use before diagnosis and colorectal cancer mortality, stratified by tumour sub-site
All tumour sub-sites combined Proximal tumours Distal/rectal tumours
Medication exposure Cases at risk
a Colorectal cancer deaths HR 95% CI HR 95% CI HR 95% CI
NSAID use
b
Never 444 81 1.00 Referent 1.00 Referent 1.00 Referent
Ever 466 62 0.88 0.62–1.24 0.55 0.32–0.92 1.32 0.83–2.10
Aspirin
c 340 50 1.14 0.77–1.69 0.75 0.41–1.37 1.64 0.96–2.78
Ibuprofen 182 19 0.51 0.26–1.00 0.09 0.01–0.69 0.94 0.45–1.97
HT use
d
Never 344 57 1.00 Referent 1.00 Referent 1.00 Referent
Ever 465 68 0.95 0.66–1.35 0.90 0.53–1.54 0.95 0.57–1.56
Oestrogen only 429 60 1.04 0.69–1.55 1.17 0.65–2.08 0.91 0.51–1.63
Oestrogens and progestin 206 26 0.92 0.43–1.97 0.72 0.17–3.16 1.19 0.46–3.09
Abbreviations : CI¼confidence interval; HR¼hazard ratio; HT¼hormone therapy; NSAID¼non-steroidal anti-inflammatory drug. Models in table above are adjusted for age
at diagnosis, body mass index, smoking status, family history of colorectal cancer, history of preventive screening and stage of disease at diagnosis.
aReported number of cases at
risk and number of colorectal cancer deaths are out of the total number of Caucasian women with non-advanced disease (n¼933) for each exposure. All HT models are
restricted to Caucasian women at least 50 years of age with non-advanced disease (n¼818). Note that not every case answered the medication questions in the interview.
bAdditionally adjusted for HT use (never, ever).
cResults by type are examined as ever use, adjusted for use of other medication types. For example, results reported for aspirin
are generated from a model comparing ever users of aspirin to never users, including ‘ever use’ of ibuprofen in the model.
dAdditionally adjusted for NSAID use (never, ever).
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likelihood of an inflammatory tumour micro-environment but
also may alter the type of tumour that initially develops. The
inhibition of the COX-2 pathway may be of particular importance;
multiple studies have observed that COX-2 expression is a negative
prognostic factor for patients with colorectal cancer and results in
high colorectal tumour loads in animal studies (Masunaga et al,
2000; Soumaoro et al, 2004; Yamac et al, 2005; Ogino et al, 2008).
An earlier report from the NHS observed that regular pre-
diagnostic aspirin use resulted in a lower than expected incidence
of tumours expressing high levels of COX-2 (Chan et al, 2007).
Use of NSAIDs before diagnosis may lead to the development of
tumours expressing lower levels of COX-2, resulting in the
diagnosis of tumours that are less aggressive and have a molecular
profile that improves survival.
Proximal colorectal tumours have a distinct molecular pheno-
type compared with distal or rectal tumours (Richman and Adlard,
2002; Azzoni et al, 2007; Benedix et al, 2010) and may, therefore,
represent a different form of colorectal disease. For example,
variation in expression of the NSAID-targeted COX-2 enzyme
according to the location of colorectal tissue has been described
previously (Dimberg et al, 1999; Wiese et al, 2003; Nasir et al,
2004), and may be a potential explanation for our observed tumour
sub-site difference. Additionally, tumours that feature a high-
degree of CpG island methylation are more likely to be found in
the proximal colon, particularly among women (Jass, 2007).
Chronic inflammation has previously been hypothesised to
accelerate the process of methylation in patients with ulcerative
colitis (Issa et al, 2001), providing a possible aetiologic link
between inflammatory processes and proximal colorectal tumours.
Although the exact molecular mechanisms behind this ‘proximal
effect’ are not presently clear, its implications have growing
importance in light of recent reports that have shown that
proximal tumours have inherently poorer prognosis than more
distal tumours (Wray et al, 2009; Benedix et al, 2010).
This study’s strengths included having a large, population-based
sample of women and the collection of detailed exposure
information for both NSAIDs and HT, including data on type,
duration and frequency of NSAID medication used, as well as
information on HT preparation type and duration of use. Follow-
up of all enrolled colorectal cancer cases was complete and
standardized. The inclusion of important covariates in our
regression models allowed us to generate measures of association
that were not biased by potentially strong confounders such as
screening. Additionally, the availability of data on tumour
characteristics at diagnosis allowed us to examine differences in
hypothesised associations across tumour sub-site.
Limitations of the study include the availability of only pre-
diagnostic information for NSAIDs and HT. It seems likely that
pre-diagnostic medication use is correlated with post-diagnostic
use, and future studies to examine these exposures independently
are warranted. Information on medication use was collected after
diagnosis, introducing the potential for incorrect recall, although
this likely affected all cases equally and as such would result
in non-differential misclassification and bias of the observed
association to the null. Only limited treatment information was
available in this population; however, SEER-reported first-course
treatment type mirrored stage of disease at diagnosis for the
majority of cases, and we accounted for extent of disease in our
analyses. We did observe that after accounting for stage of disease
at diagnosis, women diagnosed with rectal tumours were slightly
more likely to receive treatment (data not shown). Finally, we were
unable to enroll all cases immediately after diagnosis. Failure to
enroll cases in a timely manner can result in patient loss that may
lead to a lack of representativeness of the study cohort (Coghill
et al, 2009). However, we did not experience a high percentage of
patient loss, as we were able to enroll approximately 80% of cases
within 10 months of their diagnosis.
In addition to colorectal cancer-specific survival, we attempted
to explore the association between the use of these common
medications before diagnosis and all-cause mortality. We observed
HRs similar in direction to those reported for colorectal cancer
mortality, with no significant associations observed. However, the
vast majority of deaths in our cohort were due to colorectal cancer,
limiting our ability to investigate the relationship with mortality
from other causes.
Despite the inverse association consistently observed between
NSAIDs and HT in relation to colorectal cancer incidence in
women, our results suggest that this same relationship did not
uniformly extend to colorectal cancer mortality. Pre-diagnostic
NSAID use was associated with significantly improved colorectal
cancer survival among women diagnosed with proximal tumours.
However, HT was not associated with colorectal cancer survival.
Future studies should examine molecular characteristics of
diagnosed tumours, including COX-2 expression and methylation
status among regular NSAID users, and the potential interaction of
NSAID use history with patient characteristics, such as genetic
polymorphisms. Studies of the use of these common medications
in relation to survival after a diagnosis of colorectal cancer should
also be conducted among multi-ethnic cohorts of women. The
practical implication of this study is that regular NSAID use earlier
in life in persons at risk of colorectal cancer may not only prevent
disease but also may prevent more aggressive disease. This should
be considered when weighing the risks and benefits of NSAID use
as a chemopreventive therapy.
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